Artivion reports first quarter 2024 financial results

First quarter highlights: achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an increase of 17% on a gaap basis and 16% on a non-gaap constant currency basis net income was $7.5 million or $0.18 per fully diluted share and non-gaap net income was $2.6 million or $0.06 per fully diluted share in the first quarter of 2024 non-gaap adjusted ebitda increased 60% to $17.3 million in the first quarter of 2024 compared to $10.8 million in the first quarter of 2023 revised fy24 revenue guidance to 9% to 12% year-over-year growth on a constant currency basis, an increase of 0.5% at the midpoint atlanta , may 6, 2024 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended march 31, 2024. "we are very pleased with our first quarter results as we maintained growth momentum and executed on key operational priorities.
AORT Ratings Summary
AORT Quant Ranking